Once-daily valacyclovir to reduce the risk of transmission of genital herpes

Clicks: 470
ID: 114793
2004
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Once-daily suppressive therapy with valacyclovir significantly reduces the risk of transmission of genital herpes among heterosexual, HSV-2-discordant couples.
Reference Key
l2004theonce-daily Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Corey L;Wald A;Patel R;Sacks SL;Tyring SK;Warren T;Douglas JM;Paavonen J;Morrow RA;Beutner KR;Stratchounsky LS;Mertz G;Keene ON;Watson HA;Tait D;Vargas-Cortes M; ;;
Journal The New England journal of medicine
Year 2004
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/14702423
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't u.s. gov't adult female male adolescent aged middle aged Drug Administration Schedule P.H.S. Clinical Trial Randomized Controlled Trial Multicenter Study herpes genitalis / transmission infectious / prevention & control* disease transmission herpesvirus 2 anna wald lawrence corey human* / isolation & purification pmid:14702423 doi:10.1056/nejmoa035144 valacyclovir hsv transmission study group acyclovir / administration & dosage* acyclovir / analogs & derivatives* antiviral agents / administration & dosage* herpes genitalis / drug therapy* human* / physiology safe sex valacyclovir valine / administration & dosage* valine / analogs & derivatives* virus activation / drug effects

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.